We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EKF Ekf Diagnostics Holdings Plc

0.00 (0.00%)
20 Feb 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 29.35 28.60 30.10 30.00 29.30 30.00 358,775 16:35:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 66.64M -10.1M -0.0222 -13.20 133.29M
Ekf Diagnostics Holdings Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 29.35p. Over the last year, Ekf Diagnostics shares have traded in a share price range of 22.50p to 37.50p.

Ekf Diagnostics currently has 454,930,564 shares in issue. The market capitalisation of Ekf Diagnostics is £133.29 million. Ekf Diagnostics has a price to earnings ratio (PE ratio) of -13.20.

Ekf Diagnostics Share Discussion Threads

Showing 4276 to 4299 of 4800 messages
Chat Pages: Latest  180  179  178  177  176  175  174  173  172  171  170  169  Older
>20% of the Nasdaq biotech index supposedly trading for less than cash.

EKF isn't alone (all tarred with the same sort of brush) and with Mills close to maxed out on the % holding who will offer demand for shares to get this moving upwards? No wonder he's in Shares Magazine touting it to ordinary punters.

Have to wait for a catalyst or market sentiment to turn. May take a while.

Rivaldo didn't you and your favourite journalists say the same at 80+. What has changed pal?
FYI this is from the new Shares Magazine out today - Christopher Mills talking about North Atlantic's portfolio and EKF in particular:

"For example, shares in portfolio holding EKF Diagnostics (EKF:AIM) have more than halved in value over the past six months. The fact EKF continues to have exposure to Russia has also weighed on its share price.

‘People have forgotten there is a real business in EKF,’ says Mills. ‘We’ll do £16 million of EBITDA (earnings before interest, tax, depreciation and
amortisation) this year and we expect to grow EBITDA – with no revenue from Covid – to £25 million within three years. It’s crazy. Diagnostics businesses don’t trade on six times EBITDA, they trade on 12 to 15-times."

I ,m in again i believe its worth a small punt
4th May 2022
EKF's team in Cardiff working in the ISO Class 7 Clean Room for a new contract manufacturing services customer -

Wise decision my good man. filter button crowd down 60% and counting. Very wise of you chaps ignoring yours truly calling the top at 80+. Even the hard way hasn't taught you anything has it. Knock it out fellas, you're all aces in my book. LOL
James...It's a fair point regarding the filter button preventing clutter and dealing with trolls, albeit I would like to think my responses have been more relevant to EKF (than about T). Anyway, points taken and filter button deployed!

It is your call, but a number of others have made the point that the filter button is the best way to deal with trolls (as distinct from people who have a negative view of the share and make valid points which add to the collective knowledge). The last thing that we want is for a decent board to be cluttered up with rubbish.

On the subject of broker notes, I consider them more important in relation to small caps because those companies receive less coverage. So, whilst I would always take share price/revenue forecasts contained in them with a pinch of salt, they do affect investor sentiment and they often contain useful information not otherwise available to investors. Look at the sort of in depth coverage that finncap produces on life sciences companies (TSTL, BVXP etc). That is the sort of objective coverage that I think that EKF should be aiming for.

Wan with the best will in the world - avoiding a 60% collapse is not stupid in this game is it?! Re perception of the future - yes that is indeed what is all about IF such perception is correct of course. If not, a collapse ensues. You have the latter and still haven't figured out why. Worse, you still hold you're right - funny logic and all but hey happy it's not my money old chap.
Tongosti...No, that is stupid thinking.

My post above suggests the market got guidance it did not like, indeed that much we have assumed and discussed on here previously.

I would also point out that your decade quote you keep referring to is factually wrong. So, I will point out again that EKF was trading at these levels for most of 2019 and early 2020 before the pandemic.

Btw, my perception of the business, is more about the future, which in my view is surely what investing is about.

I was interested due to Chris Mills
my retirement fund
Am sure you're a decent enough chap Wan - all I am saying is that your "perception" of the business prospects is clearly wrong. That's where your souls searching should begin - but you won't would you. Do you think market is stupid enough to come down by 60% and erase a decade of progress "on no reason" at all". Do you?
This thread is about EKF and EKF prospects, and whatever you might think of me personally is irrelevant!

Happy for the likes of Tongosti to point out why I might be wrong though, which amongst the irrelevant guff appears to be indeed what we already know.....that the market does not align with some of it's investors perceptions/knowledge, which presumably include Harwood!

Ringing in my ears, and what I think I already know, is that EKF have stated that "While our approach to forecasting and guidance to analysts may be conservative, our aspirations are ambitious. Your Board is very clear that there are excellent opportunities to support accelerated growth within our core business, and to utilize our strong cash generation effectively to generate further considerable value for shareholders".

Maybe as James perhaps suggests, being conservative with analyst guidance has its 'downside' (and if so, then we have surely experienced that!), but I would also prefer that EKF beat expectations, as opposed to just meeting or missing them! So, the situation of James, and indeed the market, not liking the broker note, might in fact be down to both parties, and if the above comment still holds, at least it is conservative!

Anyway, staying with what I think I might know, I note EKF appear to have acquired (or perhaps leased) another lab in a different State in the US, which is located, perhaps coincidentally, adjacent to a very large medical centre that also controls a further 22 hospitals, 55 Urgent Care centers, 25 fast care locations, 1,875 Clinic physician practices across the State.

Anyway, we will no doubt hear more about that in due course, but I am also interested to learn of more detail regarding the overall lab strategy, and perhaps how that might also tie in with the labs set up by Verici (x1) and Renalytix (x3), which are also located in different US States.

Actually it is about what good old wan represents, not him per se aka a below average player who takes blind risks thinking he/she is far clever than the markets. Think about it.
wan you got one hell of a troll there fella !
my retirement fund
Wan, for your eyes only fella:It is impossible for a man to learn what he thinks he already knows. Epictetus
Cisk/James...I don't share your concern with regard to Harwood, but I agree the share price weakness could potentially provide an issue in terms of a low offer. However, I prefer to interpret Harwoods recent purchase as highlighting the current discount and the bright medium term prospects on offer, as well as perhaps shoring up the defence (if required).

The baked in dividend adds to the attraction in my view, plus the strong likelihood of gaining further exposure to the distribution of the Verici in specie shares, in turn potentially providing an even larger EKF payout this year, especially if in the interim Verici itself makes any announcements of further progress and/or partnerships etc.

Verici and Illumina are holding a 'fireside chat' later today -


Join us at the upcoming Bio-IT World 2022 conference. Learn how you can accelerate discovery at scale, transforming your data into deeper insights.

Illumina Featured Session
Track 8: Bioinformatics
Verici Dx Fireside Chat on Illumina Connected Analytics (ICA): “Advancing Clinical Diagnostics for Organ Transplant with AI-Powered Workflows”
Wednesday, May 4, 4:10 pm ET

Across the world, 10% of patients receiving a kidney transplant experience a clinical rejection while up to one-third experience a subclinical, or silent, rejection. Prognosis of risk of injury and resulting rejection beginning pre-transplant is crucial to guiding clinical management. Join Verici Dx and Illumina to learn how large-scale datasets and predictive artificial intelligence on a secure, scalable analysis platform help us understand immune response and other biological pathway signals, ultimately enabling more personalized transplant care.


Patti Connolly, BSc, MSc, CLS, CCRA, ACRP-CP
Chief Operating Officer
Verici Dx

Mike Kubal
Sr. Bioinformatics Staff Scientist

Real potential beyond just Kidney transplant, which will likely be of interest to for thought!

Further overview of the backdrop for healthcare and diagnostic companies.

COVID-19 testing still coming in above guidance, but current guidance is for testing to decline and hit an endemic run rate of around $100 million a quarter for the rest of the year. Importantly, the core businesses are performing well and generating high levels of confidence in the underlying health of those businesses -

Hologic, Thermo Fisher, Qiagen quarterly sales beat estimates on COVID-19 test revenue. Still, the companies expects demand for testing to decline quickly for the remainder of 2022.

Published May 3, 2022

Hologic, Roche, Thermo Fisher Scientific and Qiagen posted quarterly revenue that beat estimates on higher sales of their COVID-19 tests. Still, demand for testing likely will wane for the rest of the year, the companies warned.

The rise of COVID-19 testing sales in the quarter are in line with comments from Abbott Laboratories in its first-quarter earnings call and Quidel, which released preliminary results on April 7 and reports final figures on Wednesday.

While Quidel’s preliminary first-quarter report beat estimates, analysts noted that coronavirus testing demand going forward likely will decline.

“If this is the last quarter of surging COVID-19 sales (as our modeling suggests), it was quite a quarter to go out on,” William Blair analysts wrote of Quidel’s preliminary results.

Full article -

Would be highly surprised if this doesn't go private.
Cisk, I have exactly the same concern, as expressed in previous posts. The share price is so low, that this is a real issue.

Management needs to focus hard on improving the share price, including improving the broker analysis and detail. I did not think much of the last company broker note - and nor did the market.

Wan, I just hope Harwood doesn't decide to go above 30%. Chris Mills has previous bad form in such situations in treatment of shareholders, and wouldn't be surprised if they try and take the company out to take advantage of the price weakness...
You got one thing right pal - you're vastly less informed about it all because if you weren't you wouldn't allow your paper profits to go out in smoke would ya? As the saying goes, plenty of folks make paper money in a bull market but only a few manage to convert them into a cold hard cash. HmmmWan the man - keep it up buddy.
It would appear that some with vastly more insight and knowledge, namely Harwood Capital LLP and Harwood Capital Management, by raising their stake in EKF to 29.04%, can also see the much bigger picture.

I repeat, in part, from a previous post -

EKF was in fact trading at around these levels in share price terms for all of 2019 and the early part of 2020, but that was before the pandemic, and before the current level of investment and implementation of EKF's Growth Strategy.

So, EKF have been pared back in share price terms, to pre-pandemic when the growth prospects were different (not bad), but arguably the previous and indeed new non-COVID prospects, new skills, and new customers, are not comparable to the pre-pandemic period. But unless you take a longer term view, then the fall in the share price is all you have to talk about!

When you are unfortunately dealing with diagnosing and managing diseases, such as diabetes, that process does not stop, or indeed slow down.

Remember your bullish claims at 80+ Good to see you again :)
Chat Pages: Latest  180  179  178  177  176  175  174  173  172  171  170  169  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |